Close the acquisition of Immunomedics
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 14 Sep 2020
- Due
- 31 Dec 2020
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both the Gilead and Immunomedics Boards of Directors and is anticipated to close during the fourth quarter of 2020.”
What we found
Evidence strength A What the grades mean
Gilead Sciences confirmed in its 2021 filings that it completed the acquisition of Immunomedics during the fourth quarter of 2020.
-
A Gilead Sciences Inc. 10-Q filed 2021-05-06
“In the fourth quarter of 2020, we completed the acquisition of Immunomedics for cash consideration of $20.6 billion.” ✓ confirmed on the page
Market reaction: the shares moved +0.9% against the S&P 500 over the three sessions around the disclosure (5 May 2021 to 10 May 2021). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- Acquisition of Immunomedics
- Target
- 21 billion
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: minimum tender of at least a majority of outstanding Immunomedics shares; expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act
- Depends on
- Regulatory, Shareholder
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Gilead Sciences Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-GILD-003180 · Corrections policy